Sulfagenix
Chesterland
About Sulfagenix
Sulfagenix and its wholly-owned subsidiary, Sulfagenix Australia, are built on decades of research on modifying existing molecules to improve safety, bioavailability, and efficacy for new uses. SG1002, the company’s lead molecule, is a precursor to a natural-occurring molecule, hydrogen sulfide, for which deficits have been shown to exist in a number of serious diseases, including cardiovascular disease, type II diabetes, cancer, hypertension, Alzheimer’s Disease, asthma, and wound healing. In addition, sulfur deficiencies in the diet may be directly contributing to these diseases. Patient studies in Mexico demonstrated safety and generated encouraging results in several disease conditions including infertility, cancer, and hypercholesterolemia. Sulfagenix’s lead product, SG1002, is being developed in Phase I clinical trial (http://www.clinicaltrials.gov/ct2/show/NCT01989208) in Australia by Sulfagenix Australia to treat problems associated with heart failure.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $1.3M
- Last round: Series Unknown (Apr 2014)
- Website: sulfagenixinc.com
- Phone: +113183493851
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/sulfagenix-2179605 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.